Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899132|
Recruitment Status : Terminated (Study due for continuing review)
First Posted : May 12, 2009
Last Update Posted : September 29, 2015
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.
|Condition or disease||Intervention/treatment|
|Non-melanomatous Skin Cancer Pancreatic Cancer Small Intestine Cancer Testicular Germ Cell Tumor||Genetic: in situ hybridization Genetic: protein expression analysis Other: immunologic technique|
- To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
- To characterize TAB3 and its signaling networks that are involved in tumorigenesis.
OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
|Study Type :||Observational|
|Actual Enrollment :||180 participants|
|Official Title:||The Role of TAB3 Protein in Tumorigenesis|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Genetic: in situ hybridization
- Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ]
- Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899132
|United States, Ohio|
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106-5065|
|Study Chair:||Ge Jin, PhD||Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|